The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa
Abstract
BACKGROUND: Hidradenitis suppurativa is a painful, chronic inflammatory skin disease with few options for effective treatment. In a phase 2 trial, adalimumab, an antibody against tumor necrosis factor α, showed efficacy against hidradenitis suppurativa. METHODS: PIONEER I and II were similarly designed, phase 3 multicenter trials of adalimumab for hidradenitis suppurativa, with two double-blind, placebo-controlled periods. In period 1, patients were randomly assigned in a 1:1 ratio to 40 mg of adalimumab weekly or matching placebo for 12 weeks. In period 2, patients were reassigned to adalimumab at a weekly or every-other-week dose or to placebo for 24 weeks. The primary end point was a clinical response, defined as at least a 50% reduction from baseline in the abscess and inflammatory-nodule count, with no increase in abscess or draining-fistula counts, at week 12. RESULTS: We enrolled 307 patients in PIONEER I and 326 in PIONEER II. Clinical response rates at week 12 were significantly higher for the groups receiving adalimumab weekly than for the placebo groups: 41.8% versus 26.0% in PIONEER I (P=0.003) and 58.9% versus 27.6% in PIONEER II (P<0.001). Patients receiving adalimumab had significantly greater improvement than the placebo groups in rank-ordered secondary outcomes (lesions, pain, and the modified Sartorius score for disease severity) at week 12 in PIONEER II only. Serious adverse events in period 1 (excluding worsening of underlying disease) occurred in 1.3% of patients receiving adalimumab and 1.3% of those receiving placebo in PIONEER I and in 1.8% and 3.7% of patients, respectively, in PIONEER II. In period 2, the rates of serious adverse events were 4.6% or less in all the groups in both studies, with no significant between-group differences. CONCLUSIONS: Treatment with adalimumab (40 mg weekly), as compared with placebo, resulted in significantly higher clinical response rates in both trials at 12 weeks; rates of serious adverse events were similar in the study groups. (Funded by AbbVie; ClinicalTrials.gov numbers, NCT01468207 and NCT01468233 for PIONEER I and PIONEER II, respectively.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa
Zouboulis, C. C., Desai, N., Emtestam, L., Hunger, R. E., Ioannides, D., Juhász, I., Lapins, J., Matusiak, L., Prens, E. P., Revuz, J., et al. (2015) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12966 · Cited by 1,093
Self-citationAdalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
Menter, A., Tyring, S. K., Gordon, K., Kimball, A. B., Leonardi, C. L., Langley, R. G., Strober, B. E., Kaul, M., Gu, Y., Okun, M., et al. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2007.09.010 · Cited by 889
Self-citationHongbo, Y., Thomas, C. L., Harrison, M. A., Sam Salek, M., & Finlay, A. Y. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23621.x · Cited by 854
Jemec, G. B. E. (2012) · New England Journal of Medicine · doi:10.1056/nejmcp1014163 · Cited by 817
Self-citationRevuz, J. E., Canoui-Poitrine, F., Wolkenstein, P., Viallette, C., Gabison, G., Pouget, F., Poli, F., Faye, O., Roujeau, J. C., Bonnelye, G., et al. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.06.020 · Cited by 627
van de Putte, L. B. A., Atkins, C., Malaise, M., Sany, J., Russell, A. S., van Riel, P. L. C. M., Settas, L., Bijlsma, J. W., Todesco, S., Dougados, M., et al. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.013052 · Cited by 617
The prevalence of hidradenitis suppurativa and its potential precursor lesions
Jemec, G. B. E., Heidenheim, M., & Nielsen, N. H. (1996) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(96)90321-7 · Cited by 508
Self-citationvan der Zee, H. H., de Ruiter, L., van den Broecke, D. G., Dik, W. A., Laman, J. D., & Prens, E. P. (2011) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2011.10254.x · Cited by 472
Self-citationKimball, A. B., Kerdel, F., Adams, D., Mrowietz, U., Gelfand, J. M., Gniadecki, R., Prens, E. P., Schlessinger, J., Zouboulis, C. C., van der Zee, H. H., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-12-201212180-00004 · Cited by 428
Self-citationGrant, A., Gonzalez, T., Montgomery, M. O., Cardenas, V., & Kerdel, F. A. (2010) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.06.050 · Cited by 419
Self-citationDiagnostic delay in hidradenitis suppurativa is a global problem
Saunte, D. M., Boer, J., Stratigos, A., Szepietowski, J. C., Hamzavi, I., Kim, K. H., Zarchi, K., Antoniou, C., Matusiak, L., Lim, H. W., et al. (2015) · British Journal of Dermatology · doi:10.1111/bjd.14038 · Cited by 398
Self-citationZouboulis, C. C., del Marmol, V., Mrowietz, U., Prens, E. P., Tzellos, T., & Jemec, G. B. E. (2015) · Dermatology · doi:10.1159/000431175 · Cited by 376
Self-citationMorbidity in patients with hidradenitis suppurativa
Von Der Werth, J. M., & Jemec, G. B. E. (2001) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2001.04137.x · Cited by 344
Self-citationShlyankevich, J., Chen, A. J., Kim, G. E., & Kimball, A. B. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.09.012 · Cited by 316
Self-citationWhat causes hidradenitis suppurativa?
Ralf Paus, L., Kurzen, H., Kurokawa, I., Jemec, G. B. E., Emtestam, L., Sellheyer, K., Giamarellos-Bourboulis, E. J., Nagy, I., Bechara, F. G., Sartorius, K., et al. (2008) · Experimental Dermatology · doi:10.1111/j.1600-0625.2008.00712.x · Cited by 269
Self-citationSartorius, K., Lapins, J., Emtestam, L., & Jemec, G. B. E. (2003) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2003.05390.x · Cited by 252
Self-citationComorbidities of hidradenitis suppurativa (acne inversa)
Fimmel, S., & Zouboulis, C. C. (2010) · Dermato-Endocrinology · doi:10.4161/derm.2.1.12490 · Cited by 245
What causes hidradenitis suppurativa?
Ralf Paus, L., Kurzen, H., Kurokawa, I., Jemec, G. B. E., Emtestam, L., Sellheyer, K., Giamarellos‐Bourboulis, E. J., Nagy, I., Bechara, F. G., Sartorius, K., et al. (2008) · Experimental Dermatology · doi:10.1111/j.1600-0625.2008.00712_1.x · Cited by 230
Self-citationKimball, A. B., Jemec, G. B. E., Yang, M., Kageleiry, A., Signorovitch, J. E., Okun, M. M., Gu, Y., Wang, K., Mulani, P., & Sundaram, M. (2014) · British Journal of Dermatology · doi:10.1111/bjd.13270 · Cited by 214
Self-citationKimball, A. B., Sobell, J. M., Zouboulis, C. C., Gu, Y., Williams, D. A., Sundaram, M., Teixeira, H. D., & Jemec, G. B. E. (2016) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13216 · Cited by 202
Self-citationTreatment of Hidradenitis Suppurativa With Etanercept Injection
Adams, D. R., Yankura, J. A., Fogelberg, A. C., & Anderson, B. E. (2010) · Archives of Dermatology · doi:10.1001/archdermatol.2010.72 · Cited by 174
Hidradenitis suppurativa - characteristics and consequences
Jemec, G. B. E., Heidenheim, M., & Nielsen, N. H. (1996) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1996.tb00145.x · Cited by 145
Self-citationSafety and Tolerability of Tumor Necrosis Factor-α Inhibitors in Psoriasis: A Narrative Review
Semble, A. L., Davis, S., & Feldman, S. R. (2013) · American Journal of Clinical Dermatology · doi:10.1007/s40257-013-0053-5 · Cited by 33
van Rappard, D. C., Limpens, J., & Mekkes, J. R. (2012) · Journal of Dermatological Treatment · doi:10.3109/09546634.2012.674193 · Cited by 32
Naldi, L. (2006) · Springer eBooks · doi:10.1007/978-3-540-33101-8_8 · Cited by 27
Cited by
Sabat, R., Jemec, G. B. E., Matusiak, Ł., Kimball, A. B., Prens, E., & Wolk, K. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0149-1 · Cited by 573
Self-citationHidradenitis Suppurativa: Advances in Diagnosis and Treatment
Saunte, D. M. L., & Jemec, G. B. E. (2017) · JAMA · doi:10.1001/jama.2017.16691 · Cited by 492
Self-citationAlikhan, A., Sayed, C., Alavi, A., Alhusayen, R., Brassard, A., Burkhart, C., Crowell, K., Eisen, D. B., Gottlieb, A. B., Hamzavi, I., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.02.067 · Cited by 400
Self-citationAlikhan, A., Sayed, C., Alavi, A., Alhusayen, R., Brassard, A., Burkhart, C., Crowell, K., Eisen, D. B., Gottlieb, A. B., Hamzavi, I., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.02.068 · Cited by 399
Self-citationKimball, A. B., Jemec, G. B. E., Alavi, A., Reguiai, Z., Gottlieb, A. B., Bechara, F. G., Paul, C., Giamarellos Bourboulis, E. J., Villani, A. P., Schwinn, A., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00022-3 · Cited by 343
Self-citation
Metadata
- Authors
- Kimball, A. B., Okun, M. M., Williams, D. A., Gottlieb, A. B., Papp, K. A., Zouboulis, C. C., Armstrong, A. W., Kerdel, F., Gold, M. H., Forman, S. B., Korman, N. J., Giamarellos-Bourboulis, E. J., Crowley, J. J., Lynde, C., Reguiai, Z., Prens, E.-P., Alwawi, E., Mostafa, N. M., Pinsky, B., Sundaram, M., Gu, Y., Carlson, D. M., & Jemec, G. B. E.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-08-04
- Volume
- 375
- Issue
- 5
- Pages
- 422-434
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2503109448
- Cited by
- 807
- References
- 25
- FWCI
- 60.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.